Gene therapy for primary immune deficiencies: a Canadian perspective

The use of gene therapy (GT) for the treatment of primary immune deficiencies (PID) including severe combined immune deficiency (SCID) has progressed significantly in the recent years. In particular, long-term studies have shown that adenosine deaminase (ADA) gene delivery into ADA-deficient hematop...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xiaobai, Tailor, Chetankumar S., Grunebaum, Eyal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327566/
https://www.ncbi.nlm.nih.gov/pubmed/28261277
http://dx.doi.org/10.1186/s13223-017-0184-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327566/
https://www.ncbi.nlm.nih.gov/pubmed/28261277
http://dx.doi.org/10.1186/s13223-017-0184-y

Ejemplares similares